Joaquim Bosch-Barrera

Professor Associat Doctor

Universitat de Girona

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Joaquim Bosch-Barrera is an Associate Professor at Universitat de Girona, Spain. His research focuses on oncology, particularly the incidence and treatment of lung cancer, including biomarkers, survival trends, and the impact of oncological treatments on secondary cancers. He has published numerous articles exploring innovative therapeutic strategies and the genetic characteristics of lung cancer patients.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (14)

Jorge Joven

Professor

Universitat Rovira i Virgili

SPAIN

View details

Delvys Rodriguez-Abreu

Universidad de Las Palmas de Gran Canaria

SPAIN

View details

Florentino Hernando-Trancho. MD/PhD/Prof

Instituto de Investigación Sanitaria del Hospital Clínico San Carlos

SPAIN

View details

ATOCHA ROMERO

Associate Professor

Universidad CEU San Pablo

SPAIN

View details

Boris Duchemann

FRANCE

View details

Pedro Sousa

Universidade de Aveiro

PORTUGAL

View details

Antonio Segura-Carretero

Universidad de Granada

SPAIN

View details

Joao Pimentao

Professor Auxiliar

Faculdade de Ciências da Universidade de Lisboa

PORTUGAL

View details

Andrea De Giglio

University of Bologna

ITALY

View details

Mariano Provencio Pulla

Head of Medical Oncology Department at Puerta de Hierro University Hospital

Hospital Universitario Puerta del Hierro Majadahonda

SPAIN

View details

José Antonio Encinar

Profesor Titular de Universidad

Universidad Miguel Hernández de Elche

SPAIN

View details

Javier De Castro

HEAD OF LUNG CANCER UNIT

La Paz University Hospital

SPAIN

View details

Jose Carlos Benitez

Instituto de Investigación Biomédica de Málaga

SPAIN

View details

jose m lizcano

Universitat Autònoma de Barcelona (UAB)

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Joaquim Bosch-Barrera

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Biomarker landscape in advanced NSCLC: insights from a national prospective registry

Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain

Mitochondrial priming and response to BH3 mimetics in “one-two punch” senogenic-senolytic strategies

ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer

Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry

Lung cancer survival trends and prognostic factors: A 26-year population-based study in Girona Province, Spain

Fatty acid synthase (FASN) is a tumor-cell-intrinsic metabolic checkpoint restricting T-cell immunity

STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non-Small Cell Lung Cancer With No Actionable Gene Alterations.

Immunogenicity of COVID-19 vaccines in lung cancer patients.

Machine Learning-Assisted Recurrence Prediction for Patients With Early-Stage Non-Small-Cell Lung Cancer.

Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.

Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.

Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients

Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells

Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors

AZ12756122, a novel fatty acid synthase inhibitor, decreases resistance features in EGFR-TKI resistant EGFR-mutated NSCLC cell models.

Molecular Divergence upon <i>EGFR</i>-TKI Resistance Could Be Dependent on the Exon Location of the Original <i>EGFR</i>-Sensitizing Mutation

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics.

Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations

Collaborators (14)

Jorge Joven

Delvys Rodriguez-Abreu

Florentino Hernando-Trancho. MD/PhD/Prof

ATOCHA ROMERO

Boris Duchemann

Pedro Sousa

Antonio Segura-Carretero

Joao Pimentao

Andrea De Giglio

Mariano Provencio Pulla

José Antonio Encinar

Javier De Castro

Jose Carlos Benitez

jose m lizcano

Make your next move.